Evidence map›Paper›PMID 34997781›Full record

ArticleJournal of labelled compounds & radiopharmaceuticals2022

Exploring the enzyme-catalyzed synthesis of isotope labeled cyclopropanes.

Malvika Sardana, Kim S Mühlfenzl, Sylvia T M Wenker, Christian Åkesson, Martin A Hayes, Charles S Elmore, Subhash Pithani

Abstract read
In one paragraph

Article in Journal of labelled compounds & radiopharmaceuticals, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Exploring the enzyme-catalyzed synthesis of isotope labeled cyclopropanes.Journal of labelled compounds & radiopharmaceuticals · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Malvika SardanaEarly Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden.ORCID 0000-0002-6838-4392
Kim S MühlfenzlEarly Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden.ORCID 0000-0003-3700-0891
Sylvia T M WenkerEarly Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden.ORCID 0000-0003-4259-2529
Christian ÅkessonEarly Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Martin A HayesDiscovery Sciences, BioPharmaceutical R&D, AstraZeneca, Gothenburg, Sweden.ORCID 0000-0002-2640-8464
Charles S ElmoreEarly Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden.ORCID 0000-0001-7434-8307
Subhash PithaniEarly Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden.ORCID 0000-0002-5291-2138

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cyclopropanes are commonly employed structural moieties in drug design since their incorporation is often associated with increased target affinity, improved metabolic stability, and increased rigidity to access bioactive conformations. Robust chemical cyclopropanation procedures have been developed which proceed with high yield and broad substrate scope, and have been applied to labeled substrates. Recently, engineered enzymes have been shown to perform cyclopropanations with remarkable diastereoselectivity and enantioselectivity, but this biocatalytic approach has not been applied to labeled substrates to date. In this study, the use of enzyme catalysis for the synthesis of labeled cyclopropanes was investigated. Two readily available enzymes, a modified CYP450 enzyme and a modified Aeropyrum pernix protoglobin, were investigated for the cyclopropanation of a variety of substituted styrenes. For this biocatalytic transformation, the enzymes required the use of ethyl diazoacetate. Due to the highly energetic nature of this molecule, alternatives were investigated. The final optimized cyclopropanation was successfully demonstrated using n-hexyl diazoacetate, resulting in moderate to high enantiomeric excess. The optimized procedure was used to generate labeled cyclopropanes from

Indexed as

CyclopropanesIsotopesBiocatalysisCatalysisMolecular StructureStereoisomerismCyclopropanesIsotopesbiocatalysiscyclopropanationdiazoacetatesenzyme catalysisisotopic labelingstereoselectivity

Identifiers

PMID34997781
PMCPMC9305206

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.